Pain & Central Nervous System Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain & Central Nervous System Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Rheumatoid Arthritis
Azulfidine Entabs Approved for Treatment in Children
September 9th, 2000
Pharmacia Corp., Peapack, New Jersey, announced that the U.S. Food and Drug Administration (FDA) has approved an indication for Azulfidine Entabs (sulfasalazine delayed release tablets, USP) in the treatment of children (ages six to 16) with juvenile rheumatoid arthritis (RA) involving five or more diseased joints who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs (NSAIDs). Azulfidine Entabs is the only formulation of sulfasalazine approved by the FDA for the treatment of both juvenile and adult RA. The enteric-coated formulation of Azulfidine Entabs was specifically designed to reduce the likelihood of nausea and stomach...
Source: Pain & Central Nervous System Week (2000-09-09)
|
